Search results
Results from the WOW.Com Content Network
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
An unusual side effect of digoxin is a disturbance of color vision (mostly yellow and green) called xanthopsia. Vincent van Gogh's "Yellow Period" may have somehow been influenced by concurrent digitalis therapy. Other oculotoxic effects of digoxin include generalized blurry vision, as well as seeing a "halo" around each point of light.
Consumer Reports states that PriceGrabber places the ads and pays a percentage of referral fees to CR, [25] who has no direct relationship with the retailers. [26] Consumer Reports publishes reviews of its business partner and recommends it in at least one case. [27]
SEE ALL Consumer Reports product reviews. ... It has three burners, electronic ignition, and two side shelves. Permasteel PG-40301-BK. Permasteel PG-40301-BK $355.74 at Wayfair.
This is a list of adverse effects of risperidone. Risperidone , sold under the brand name Risperdal among others, is an antipsychotic . [ 1 ] It is used to treat schizophrenia , bipolar disorder , and irritability associated with autism .
However, a retrospective chart review suggests the data for this cutoff are slim and a cutoff of CrCl < 40 ml/min would be more appropriate. [42] Many of the severe side effects of this drug are more common in the elderly and those with renal impairment, as this causes the drug to be retained in the body and reach higher systemic levels.
The company also publishes the Consumers’ Guide to Top Doctors, providing a list of recommended specialists in the 53 largest metro areas of the U.S. as well as the Consumers' Guide to Hospitals, providing ratings for about 4,500 U.S. acute-care hospitals, which it first published in 1988. The Guide to Top Doctors was first published in 1999.
Formulations of delayed-release budesonide are an effective treatment for mild-to-moderately active Crohn's disease involving the ileum and/or ascending colon. [25] A Cochrane review found evidence for up to three months (but not longer) of maintenance of remission in Crohn's disease, concluding that budesonide is not effective for maintenance of remission in CD.